AbCellera Biologics (ABCL) Initiation of Coverage
Investment Summary
- AbCellera Biologics (ABCL) has undergone a major transformation over the past three years, shifting from a partner-driven antibody discovery platform to a clinical-stage biotechnology company with a growing internal pipeline.
- Revenue declined sharply post-COVID-19 as pandemic-related antibody royalties ceased, but the company maintained a strong liquidity position, supported by significant government funding and strategic partnerships.
- The company completed its transition to a clinical-stage biotech in 2025, initiating clinical trials for its first two internal drug candidates (ABCL635 and ABCL575), and further expanding its pipeline with additional IND-enabling programs.
- Strategic partnerships remain important, with new high-value T-cell engager (TCE) deals signed with Vertex and Jazz Pharmaceuticals in 2026, bringing in over $110M in upfront payments and potential for substantial downstream value.
- ABCL635 reported positive Phase 2 top-line results in August 2026, and the ABCL575 Phase 1 readout is expected in Q4 2026. Net losses continue due to high R&D investment, but the company retains a robust cash runway.
Business Overview
AbCellera Biologics specializes in the discovery and development of antibody-based medicines, leveraging proprietary platforms for challenging targets such as GPCRs, ion channels, and T-cell engagers. Historically, revenue was generated from research fees, milestones, and royalties through partnerships with major pharmaceutical companies. The company has now pivoted to focus on developing its own internal pipeline, aiming to capture greater long-term value from wholly owned or co-developed assets. Manufacturing capabilities were expanded with the completion of a GMP facility in 2025.
Financial Snapshot: Fiscal Years (FY Ended December 31)
| Fiscal Year | Revenue ($M) | Net Income/Loss ($M) | R&D Expense ($M) | SG&A Expense ($M) | Cash & Equiv. ($M) | Partner-Initiated Programs | Molecules in Clinic | Employees | Notes |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | 75.1 | -146.4 | 186.8 | 83.2 | 533.8 | 104 | 19 | 562 | Includes $36M litigation settlement |
| 2024 | 28.8 | -162.9 | 167.3 | 85.5 | 625.6 | 96 | 16 | ~600 | Revenue down post-COVID royalties |
| 2023 | 38.0 | -146.4 | 175.7 | 75.2 | 760.6 | 87 | 13 | 586 | No COVID royalty revenue |
Financial Snapshot: Quarterly Actuals (Most Recent Periods)
| Quarter | Revenue ($M) | Net Loss ($M) | R&D Expense ($M) | SG&A Expense ($M) | Cash & Marketable Securities ($M) | Available Liquidity ($M) | Partner-Initiated Programs | Molecules in Clinic | Notes |
|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 | 4 | -55 | 46 | 14 | 567 | >675 | - | - | $56M Jazz upfront received in cash |
| Q1 2026 | 8 | -43 | 47 | 12 | 531 | 655 | - | - | - |
| Q2 2025 | 17 | -35 | 39 | - | 580 | 750 | 102 | 18 | $10M one-off licensing fee |
| Q1 2025 | 4 | -46 | 43 | - | 630 | 810 | 97 | 16 | - |
Pipeline Progression (as of 2026)
| Program | Stage | Indication / Target | Key Milestones / Status |
|---|---|---|---|
| ABCL635 | Phase 2 | Vasomotor symptoms (menopause) | Positive Phase 2 top-line results reported August 2026 |
| ABCL575 | Phase I | OX40 ligand antagonist (atopic dermatitis) | Dosing completed; readout expected Q4 2026 |
| ABCL688 | IND-enabling | Autoimmunity (undisclosed) | Phase I/II start expected 2027 |
| ABCL386 | IND-enabling | Oncology (undisclosed) | Phase I/II start expected 2027 |
| TCE Platform | Preclinical/BD | Oncology, Autoimmunity | Vertex/Jazz deals signed; >$110M upfront |
Bullish and Bearish Points
| Bullish Points | Bearish Points |
|---|---|
| Strong liquidity position ($533.8M FY2025; $567M Q2 2026; >$675M available) | Continued operating/net losses (-$146.4M FY2025; -$55M Q2 2026) |
| Transition to clinical-stage with internal programs in trials | No marketed proprietary drugs; all internal programs are early-stage |
| Multiple high-value TCE partnerships (Vertex, Jazz; $110M+ upfront) | Revenue highly dependent on unpredictable milestone and royalty payments |
| Completed major capital investments (GMP facility) | High R&D spend and negative operating cash flow expected in near-to-medium term |
| Diversified portfolio: 104 partner-initiated programs, 19 molecules in clinic | Intense competition in antibody therapeutics; risk of clinical failure |
| Government support: >$347.9M in non-dilutive funding since 2020 | Impairment charges on acquired intangibles in FY2024; risk of further write-downs |
| Platform validated by 19 molecules reaching the clinic (internal + partner) | Attrition in partner programs; reporting on partner programs to cease after 2026 |
Positive and Negative Catalysts
| Positive Catalysts | Negative Catalysts |
|---|---|
| ABCL635 late-stage plan and ABCL575 Phase 1 readout (Q4 2026) | Clinical trial failures or delays for internal pipeline |
| Out-licensing or partnership deals for internal programs | Reduced pace of new partnerships or partner program attrition |
| Advancement of ABCL688 and ABCL386 into clinical trials (2027) | Regulatory setbacks or inability to progress to late-stage |
| Realization of milestone/royalty payments from partner programs | Failure to achieve commercial success with internal pipeline |
| Additional government grants or non-dilutive funding | Increased competition or loss of key partnerships |
| Successful monetization of manufacturing capabilities | Adverse legal outcomes or IP challenges |
| Additional TCE BD deals (Vertex, Jazz) | Delay in IND filings for ABCL688/386 |
Top Questions to Ask Before Investing
- How will ABCL635 move into late-stage development after its positive Phase 2 results, and how does it compare with approved oral NK3R drugs?
- How will AbCellera differentiate ABCL635 in terms of safety, dosing convenience, and commercial positioning?
- What is the timeline and likelihood for ABCL575 and other pipeline assets to reach pivotal studies or commercialization?
- How sustainable is AbCellera’s liquidity position given ongoing net losses and high R&D spend?
- What are the terms and potential downstream economics of the Vertex and Jazz TCE partnerships?
- How will the company manage operational capacity as the pipeline expands to multiple clinical-stage programs?
- What is the competitive landscape for non-hormonal VMS treatments and TCEs in autoimmunity/oncology?
- What are the key regulatory risks and requirements for advancing ABCL635 and other assets into late-stage trials?
- How predictable are future milestone and royalty payments from the partner portfolio, and what is the timeline for potential material contributions?
- What led to the impairment charges in FY2024, and is there risk of further asset write-downs if pipeline programs do not advance?
